FDA Approves Pralsetinib for NSCLC with RET Gene Fusions

On August 9, the US Food and Drug Administration (FDA) approved pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

For more information read the FDA announcement.

Posted 8/10/2023